Tolebrutinib failed to lower disability progression risk in primary progressive MS in a Phase 3 trial, with data shown at ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system. MS disrupts the flow of information between the ...

New clinical trial data suggest vidofludimus calcium can target key mechanisms underlying progressive multiple sclerosis.

Persistent inflammation may influence neurodegeneration through microglial activation, yet evidence remains hypothesis driven ...

Learn how early diagnosis and modern therapies can prevent Multiple Sclerosis from leading to long-term disability.

Roche. Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease. 2026 Feb 16. Accessed 2026 Feb 16.

In the rapidly moving field, questions remain regarding long-term safety, durability of remission, and the FDA’s approach to ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026 Viking Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.38 EPS, expectations were $-0.

Blocked from reporting on U.S. Education Linda McMahon's visit to a Colts Neck school, the Asbury Park Press filed open ...

Background Motor and cognitive dysfunctions are common and disabling features in multiple sclerosis (MS) that remain challenging to treat. Here, we aimed to explore the effect of exergames as a ...

Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, February 11 ...

Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to ...